Allergy

NS-229 is a Janus kinase 1 (JAK1) inhibitor being investigated in eosinophilic granulomatosis with polyangiitis, a rare autoimmune condition that can cause severe allergic and asthmatic symptoms through inflammation of nerve cells.

The smartphone application-led delabeling also did not delay surgeries or procedures in the evaluated clinics.

Children who received antibiotics between birth and 2 years of age were more likely to develop food allergies, allergic rhinitis, and asthma, but not neurodevelopmental conditions.

Multiple phase 3 clinical trials demonstrated dupilumab’s (Dupixent; Regeneron, Sanofi) effectiveness in reducing hives and itch in patients with chronic spontaneous urticaria compared with placebo.

Authors of a review published in The Journal of Allergy and Clinical Immunology emphasized that blood eosinophil count and fractional exhaled nitric oxide cannot be relied on.

In mouse models, researchers identified that immune cells within the intestine may prevent unwarranted attacks against harmless food allergens.

At 12 and 24 months, there were 56.9% and 73.5% reductions in food-specific immunoglobulin E (IgE).

Symptoms occur when airborne irritants enter the eyes, nose, and throat, causing an allergic reaction.

Approximately 74% of patients with chronic rhinosinusitis with nasal polyps receiving depemokimab across 2 trials did not need additional intervention.

Although dietary changes have historically been a key approach to managing eosinophilic esophagitis, their limitations highlight the need for pharmacologic treatments.

The authors note that further research is needed to clarify cost-effectiveness, long-term adherence, and psychosocial impacts of oral immunotherapy.

Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.

According to a news release, this marks the first significant innovation in epinephrine delivery for this patient population is more than 35 years.

Tezepelumab demonstrated efficacy compared with placebo when treating patients with chronic rhinosinusitis with nasal polyps.

The updated indication now includes pediatric patients aged 5 through 11 years.

Health care professionals and patients must recognize that rapid administration of adrenaline is the only first-line treatment for anaphylaxis.

Lawsuits were initiated against the pharmacy and prescriber.

The FDA-approved treatment did not cause as many adverse events as immunotherapy when treating patients with multi-food allergy.

In children aged 1 to 3 years, the VP250 peanut patch was superior to placebo in the desensitization to peanuts and increasing the peanut dose that triggers allergic symptoms.

The authors are optimistic that these findings may help develop defenses to prevent food allergies in at-risk infants.

After gradually consuming increased doses of peanut butter, children who could initially tolerate about half a peanut could consume 3 tablespoons without an allergic reaction.

The authors are optimistic that this method can be replicated to identify other allergens that manifest into eosinophilic esophagitis (EoE).

Intranasal epinephrine spray offers a needle-free option for anaphylaxis treatment.

The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.

Knowing which patients are at higher risk for developing urticaria by analyzing their history of food allergies could lead to better outcomes in this population.

Proven effective in the treatment of atopic dermatitis (AD) and other allergic conditions, these study results confirm the ability of dupilumab to improve symptoms in children with other concurrent conditions.

Prevalence increased across all subgroups among children and adolescents, with decreases observed in young adults and elderly populations.

The study also found that HSSPs minimize health costs and provide additional revenue for health systems.

Exposure to pollutants PM2.5 and NO2 was found to increase the likelihood of developing a peanut allergy and of the allergy persisting.